Loading…
French operator of nursing homes, retirement residences and post-acute rehabilitation clinics across Europe, rebranded from Orpea after restructuring.
French operator of nursing homes, retirement residences and post-acute rehabilitation clinics across Europe, rebranded from Orpea after restructuring.
Care costs are paid largely by public health and social budgets while residents pay for accommodation, so tariff-setting and staffing rules shape results. A 2022 abuse scandal and a 2023 financial rescue, in which creditors and public-backed investors including Caisse des Dépôts took control, led to the new name in 2024.
In one line: A French Brookdale Senior Living / Genesis Healthcare.
Moat: narrow (regulatory licence, scale, installed base). Licensed bed capacity and real-estate footprint across Europe, but reputational damage and heavy debt from past scandal.
Headquarters: Puteaux, France · Founded: 1989 · Employees: 84,586
Size Emeis (EMEIS.PA) is a France Health Care company (Medical/Nursing Services) with a market value of $1.94B, the 108th largest of 206 France companies the cockpit tracks. Shares closed at €10.73 on 6 Nov 2026.
Performance Over six months the shares fell 30.0%, against +25.1% for the median peer and -0.4% for the France market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 3.9% over the last twelve months (peer median +4.9%); the operating margin is 3.0% (peer median 6.7%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 1.9× (9th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.4 points below its cost of capital (5.7% WACC).
Next results Next results expected around 7 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €6.00B | €5.90B | €5.64B | €5.20B | €4.68B |
| Revenue growth | — | +5% | +8% | +11% | — |
| Gross profit | €219M | €152M | €14.8M | -€11.6M | -€91.4M |
| EBITDA | €838M | €778M | €697M | €547M | €141M |
| Net income | -€201M | -€298M | -€412M | €1.35B | -€4.03B |
| Free cash flow | €335M | €422M | €174M | -€90.2M | €251M |
| Capital expenditure | €266M | €258M | €298M | €456M | €159M |
| Total debt | n/a | €8.43B | €8.86B | €9.16B | €13.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Emeis EMEIS.PA | $1.94B | -30% | +4% | 3% | 1.6× | 21.3% |
| Clariane CLARI.PA | $1.40B | -20% | +1% | 6% | 1.6× | 6.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EMEIS.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.6% | +8.0% | 9th highest of 21 |
| 6-month return | -30.0% | +25.1% | 2nd lowest of 21 |
| Distance from 52-week high | -32.9% | -13.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +3.9% | +4.9% | 11th highest of 21 |
| Operating margin | 3.0% | 6.7% | 9th lowest of 21 |
| EV / Sales | 1.6× | 1.9× | 9th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 21.3% | 10.1% | 5th most demanding of 16 |
| Growth delivered (Del g) | +8.5% | +8.9% | 8th lowest of 16 |
| Hurdle (Req g minus delivered) | +12.8 pp | +6.8 pp | 5th most demanding of 16 |
| ROIC minus cost of capital | -4.4 pp | -3.1 pp | 8th lowest of 20 |
| EV / EBITDA | 11.8× | 13.2× | 6th cheapest of 14 |
| Net debt / EBITDA | 8.9× | 1.3× | 3rd most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | 1.6× | 21.3% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 1.5× | 2.4% | -1.1% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 0.3× | n/a | n/a |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 2.0× | 6.7% | -6.1% |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 4.2× | n/a | n/a |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 7.4× | 41.9% | +26.9% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 3.2× | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 2.4× | 56.0% | +8.9% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | 22.1× | n/a | n/a |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 2.5× | 21.6% | +14.6% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 0.7× | 15.0% | -5.1% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 1.7× | 1.7% | +7.7% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 1.5× | 4.9% | +13.2% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 16.8× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | 0.7× | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | 5.9× | n/a | n/a |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 1.3× | -4.5% | +2.0% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 2.7× | 19.9% | +13.0% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 1.6× | 6.7% | +6.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 0.9× | 10.1% | +2.1% |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 1.6× | 13.4% | +10.2% |